India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
It is a recombinant nanoparticle protein-based vaccine
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
The country’s vaccine production has more than doubled since April and is set to touch 300 million doses next month
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
It will also manage test result documentation for employees who are not vaccinated, sending weekly reminders and employer notification
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
The first lot of IPV will be supplied to the government this month as per the requirement of the Health Ministry
Subscribe To Our Newsletter & Stay Updated
